Additional file 1: Table S1. of Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study

Number and distribution of discharge diagnoses by type of admission, in hospitalizations ending with death. Table S2. Relation between mortality, hospitalizations for respiratory failure and clinical characteristics. Hazard Ratio (HR), with 95 % Confidence Interval (95 % CI). (DOCX 30 kb

Additional file 1 of Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires

Additional file 1

Data_Sheet_1_Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia.docx

IntroductionFrontotemporal dementia (FTD) is an extremely heterogeneous and complex neurodegenerative disease, exhibiting different phenotypes, genetic backgrounds, and pathological states. Due to these characteristics, and to the fact that clinical symptoms overlap with those of other neurodegenerative diseases or psychiatric disorders, the diagnosis based only on the clinical evaluation is very difficult. The currently used biomarkers help in the clinical diagnosis, but are insufficient and do not cover all the clinical needs.MethodsBy the means of a new immunoassay, we have measured and analyzed the proNGF levels in 43 cerebrospinal fluids (CSF) from FTD patients, and compared the results to those obtained in CSF from 84 Alzheimer’s disease (AD), 15 subjective memory complaints (SMC) and 13 control subjects.ResultsA statistically significant difference between proNGF levels in FTD compared to AD, SMC and controls subjects was found. The statistical models reveal that proNGF determination increases the accuracy of FTD diagnosis, if added to the clinically validated CSF biomarkers.DiscussionThese results suggest that proNGF could be included in a panel of biomarkers to improve the FTD diagnosis.</p

Demographics and clinical features of the Irish, Italian and French ALS population cohorts and the corresponding tertiary referral cohorts.

<p>Demographics and clinical features of the Irish, Italian and French ALS population cohorts and the corresponding tertiary referral cohorts.</p

Characteristics of European registers participating in the study.

<p>Characteristics of European registers participating in the study.</p

Clinical features of ALS patients.

<p>ALS, amyotrophic lateral sclerosis. >UMN, higher upper motor neuron burden. </p

Example of the CTh boundaries of an ALS patients.

<p>Axial and coronal T1-weighted images of an ALS patient. White matter surface (yellow line) and pial surface (red line), which are the boundaries of cerebral cortex, have been automatically obtained by Freesurfer. The primary motor area (blu) has been automatically labeled according to the Desikan/Killiany Atlas.</p

Vertex-wise analysis of CTh in ALS patients related to HC.

<p>ALS patients revealed cortical thinning in bilateral precentral cortex, bilateral middle frontal gyrus, right superior temporal gyrus and right occipital cortex. The colour bar scale represents t values.</p

Mean whole brain and primary motor areas cortical thickness in ALS subgroups.

*<p>p<0.05 vs HC, § p≤0.01 vs HC, Ω p<0.005 vs HC.</p><p>CTh, cortical thickness, expressed in millimeters (mean ± SD); ALS, amyotrophic lateral sclerosis; HC, Healthy Controls; >UMN-ALS, higher upper motor neuron burden; </p

Mean whole brain and primary motor areas cortical thickness in ALS and HC.

<p>CTh, cortical thickness, expressed in millimeters (mean ± SD); ALS, amyotrophic lateral sclerosis; HC, healthy controls; n s, not significant.</p